American regulators have recently been taking more of a cost-benefit approach to risk, whereas Europeans are putting more emphasis on precautions, whatever the cost.
The researchers suggest instead using a cost-benefit approach - such as how many cases of remission a drug can provide, or how many relapses it might prevent.